Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373650" target="_blank" >RIV/00216208:11130/17:10373650 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/17:10373650

Result on the web

<a href="https://doi.org/10.1007/s40291-017-0277-9" target="_blank" >https://doi.org/10.1007/s40291-017-0277-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s40291-017-0277-9" target="_blank" >10.1007/s40291-017-0277-9</a>

Result language

angličtina

Original language name

Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Original language description

Minimal residual disease (MRD) is the most important independent prognostic factor in acute lymphoblastic leukemia (ALL). Since it has been implemented into in treatment stratification strategies, cure rates have improved significantly for all age groups. Real time quantitative (RQ)-PCR of clonal immunoglobulin and T-cell receptor gene rearrangements using allele-specific primers is currently regarded as the gold standard for MRD analysis in ALL, as it is not only highly sensitive and specific but also provides accurate MRD quantification. Following recent advances in next-generation sequencing (NGS), much attention has been devoted to the development of NGS-based MRD assays. This new technique can enhance sensitivity provided that sufficient numbers of cells are analyzed. Recent reports have shown that NGS-MRD also tends to be more specific for relapse prediction than RQ-PCR. In addition, NGS provides information on the physiological B- and T-cell repertoire during and after treatment, which has been shown to be prognostically relevant. However, before implementation of NGS-MRD detection in clinical practice, several issues must be addressed and the whole workflow needs to be standardized, including not only the analytical phase (spike-in calibrators, quality controls) but also the pre-analytical (e.g. sample preparation) and the post-analytical phases (e.g. bioinformatics pipeline, guidelines for correct data interpretation). These topics are currently addressed by a European network, the EuroClonality-NGS Consortium. In conclusion, NGS is a promising tool for MRD detection with the potential to overcome most of the limitations of RQ-PCR and to become the new gold standard for MRD detection in ALL.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

<a href="/en/project/NV16-32568A" target="_blank" >NV16-32568A: The development and standardization of method for analysis of antigen receptor gene rearrangements using next generation sequencing for use in immunoh</a><br>

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2017

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Molecular Diagnosis and Therapy

ISSN

1177-1062

e-ISSN

—

Volume of the periodical

21

Issue of the periodical within the volume

5

Country of publishing house

NZ - NEW ZEALAND

Number of pages

12

Pages from-to

481-492

UT code for WoS article

000411332800002

EID of the result in the Scopus database

2-s2.0-85018365101